Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate used to treat adult patients with:

• metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.
• locally advanced/metastatic urothelial cancer (mUC) who have previously treated with a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. 

Recommended Dosage: The recommended dose is 10 mg/kg administered as an intravenous infusion once a week on Days 1’st and 8’th of 21-day treatment cycles. Continue treatment until the disease is progressive or unacceptable toxicity occurs. Do not administer Trodevy injection at doses greater than 10 mg/kg. Administer it as an intravenous infusion only. Do not administer this drug as an intravenous push or bolus. 

• Sacituzumab Govitecan-hziy can cause severe or life-threatening neutropenia. Withhold it for absolute neutrophil count below 1500/mm3 on Day 1’st of any cycle or neutrophil count below 1000/mm3 on Day 8’th of any cycle. Withhold it for neutropenic fever. 
• Trodelvy breast cancer drug can cause severe diarrhea. Withhold it for Grade 3-4 diarrhea at the juncture of scheduled treatment administration and resume when resolved to ≤ Grade 1.
• Sacituzumab Govitecan-hziy can cause severe and life-threatening hypersensitivity. Pre-infusion drug for patients receiving sacituzumab govitecan hziy is recommended. Observe patients precisely for infusion-related reactions during each infusion and for at least 30 minutes following completion of each infusion. 
• Patients who are homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at greater risk for neutropenia and may be at greater risk for other adverse reactions following starting of trodelvy 180 mg treatment.
• Precisely assess patients with reduced UGT1A1 activity for the severe neutropenia. The apt dose for patients who are homozygous for UGT1A1*28 is not specified and should be considered based on the tolerance to treatment. 
• Mechanism of action suggest that the trodelvy therapy can be responsible for causing teratogenicity and/or embryo-fetal lethality in case administered to a pregnant woman.

What documents are required to import TRODELVY to India?

TRODELVY (sacituzumab govitecan-hziy) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation needed in order to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients id proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is TRODELVY available in India?

TRODELVY (sacituzumab govitecan-hziy injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

• On availability in India ( Kolkata, Hyderabad, Mumbai, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
• Medicine Price.
• Finding Authentic and reliable source from USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

TRODELVY can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of TRODELVY (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for trodelvy price in India. 

We take guarantee of quality as well as delivery in avery  corner in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the TRODELVY (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network has potential to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.